Gastrointestinal stromal tumours (GISTs): French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO)

Landi, Bruno; Blay, Jean‐Yves; Bonvalot, Sylvie; Brasseur, Mathilde; Coindre, Jean Michél; Emile, Jean François; Hautefeuille, Vincent; Honoré, Charles; Lartigau, É.; Mantion, Georges; Pracht, Marc; Cesne, Axel Le; Ducreux, Michel; Bouché, Olivier

doi:10.1016/j.dld.2019.07.006

Cited by 61 publications

(76 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…According to the European society, National Thesaurus of Digestive Cancerology (TNCD), CT scan is recommended for studying tumors characteristics and extensions, endoscopic ultrasonography (EUS), MRI and positron emission tomography (PET-scan) are optional [ 6 ].…”

Section: Discussionmentioning

confidence: 99%

“…Recurrences after primal surgery can occur at any site but mainly in the liver or the peritoneum; and they are most likely to appear in the range of 3 years to 5 after surgery or adjuvant therapy been completed. Unfortunately; due to lacking data or consensus; follow up and monitoring protocol are not standardized, but the French guidelines proposes at least an annual clinical examination and abdominal CT imaging and an optional close follow up for high risk patients or undergoing adjuvant therapies ( Table 1 ) [ 6 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Neurofibromatosis type 1 associated multiple and cystic gastrointestinal tumors: 02 case reports

Rahou

Miry

Bennani

et al. 2020

International Journal of Surgery Case Reports

View full text Add to dashboard Cite

Highlights Surgery is the Gold standard for GIST's treatment , but microscopic margins can be acceptable for borderline tumors Multiple GISTs with NF1, multiples surgeries for multiples recurrences or multiples localization might be needed. Need for furthermore study of this subpopulation of GIST’s and a precise molecular identification that could lead to a new era of adjuvant or neoadjuvant therapies.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Neurofibromatosis type 1 associated multiple and cystic gastrointestinal tumors: 02 case reports

Rahou

Miry

Bennani

et al. 2020

International Journal of Surgery Case Reports

View full text Add to dashboard Cite

show abstract

“…The main differential malignant diagnoses for an antral gastric mass are adenocarcinoma, 37 gastric carcinoma, 38 gastric lymphoma, 39 gastrointestinal stromal tumor (GIST), 40 and neuroendocrine tumors 41 in adults and children. The CT scan misdiagnoses gastric tumor in 23% of these cancers 37 .…”

Section: To the Editormentioning

confidence: 99%

“…Endoscopy showed sensitivity of 60‐61% for the detection of malignancy, whereas endoscopic sensitivity decreased to 20.8‐27% for gastric lymphoma 39 . Endoscopic biopsies are usually negative in GIST 40 . However, these diagnoses remain extremely rare in children and adolescents 42 .…”

Section: To the Editormentioning

confidence: 99%

Extrapancreatic primary solid pseudopapillary tumor in the gastric antrum: Case report

Lemoine¹,

Asmandar²,

Boutroux

et al. 2020

Pediatric Blood & Cancer

View full text Add to dashboard Cite

“…Up to 85% of GISTs acquire mutations in the KIT gene and 3-18% in the platelet-derived growth factor receptor A (PDGFRA) gene. 2 GIST responds to treatment with targeted KIT/PDGFRA inhibitors such as imatinib mesylate. [3][4][5] However, up to 40-50% of GISTs develop secondary resistance after an average of 24 months of imatinib treatment.…”

Section: Introductionmentioning

confidence: 99%

<p>Chloroquine Combined with Imatinib Overcomes Imatinib Resistance in Gastrointestinal Stromal Tumors by Inhibiting Autophagy via the MAPK/ERK Pathway</p>

Zheng¹,

Shu

et al. 2020

OTT

View full text Add to dashboard Cite

Background: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract. However, up to 40-50% of GISTs develop secondary resistance after an average of 24 months of imatinib treatment. It has been reported that autophagy can promote the survival of GIST cells and induce drug resistance. Presently, the specific mechanism of autophagy in GISTs with imatinib resistance is not clear. Materials and Methods: The cell-counting kit (CCK)-8 method and flow cytometry were used for in vitro drug sensitivity testing and autophagy level detection. Detection of the apoptosis level was by flow cytometry with the annexin V Kit. Western blotting was used to analyze the role of autophagy and apoptosis in GIST cells with CQ alone, imatinib alone, or in combination, and to analyze MAPK pathway expression. In vitro results were confirmed by in vivo experiments using the mice model. Hematoxylin and eosin and immunohistochemical staining were used to detect the pathological characteristics and immunophenotype of the transplanted tumor. Detection of KIT and PDGFRA gene mutations in the transplanted imatinib-resistant GIST was done by denaturing high performance liquid chromatography (DHPLC) and direct sequencing. ERK and KIT expression and regulation levels were detected by Western blotting. Results: In vitro and vivo experiments, the autophagy level of imatinib-resistant cells was higher than that of normal cells; CQ combined with imatinib can promote apoptosis by blocking autophagy of imatinib-resistant cells. In the meanwhile, we found that the phosphorylation level of ERK may be related to autophagy. Conclusion: Our data suggest that autophagy through the MAPK/ERK pathway may play a pivotal role in imatinib-resistant GIST proliferation. Moreover, combining an autophagy inhibitor with imatinib may be a potential valuable strategy in overcoming acquired resistance in GIST patients.

show abstract

Gastrointestinal stromal tumours (GISTs): French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO)

Cited by 61 publications

References 34 publications

Neurofibromatosis type 1 associated multiple and cystic gastrointestinal tumors: 02 case reports

Neurofibromatosis type 1 associated multiple and cystic gastrointestinal tumors: 02 case reports

Extrapancreatic primary solid pseudopapillary tumor in the gastric antrum: Case report

<p>Chloroquine Combined with Imatinib Overcomes Imatinib Resistance in Gastrointestinal Stromal Tumors by Inhibiting Autophagy via the MAPK/ERK Pathway</p>

Contact Info

Product

Resources

About